Supernus Pharmaceuticals Files 8-K on Financials

Ticker: SUPN · Form: 8-K · Filed: 2025-07-22T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, sec-filing, operations

Related Tickers: SUPN

TL;DR

SUPN filed an 8-K on 7/22/25 with financial results and exhibits.

AI Summary

On July 22, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial performance. The report was filed with the SEC under the 1934 Act.

Why It Matters

This filing provides investors with crucial, up-to-date financial information and operational results for Supernus Pharmaceuticals, Inc., enabling informed investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual events or significant changes.

Key Numbers

Key Players & Entities

FAQ

What specific financial statements are included in this 8-K filing?

The filing indicates that financial statements and exhibits are included, but the specific details of these statements are not enumerated in the provided text.

What is the primary purpose of this 8-K filing for Supernus Pharmaceuticals, Inc.?

The primary purpose is to report on the company's Results of Operations and Financial Condition as of July 22, 2025.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is the principal executive office address for Supernus Pharmaceuticals, Inc.?

The principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.

Does this filing indicate any changes to the company's name or address since the last report?

The filing mentions 'Not Applicable' for former name or former address, if changed since last report, suggesting no recent changes were reported in this section.

From the Filing

0001356576-25-000046.txt : 20250722 0001356576-25-000046.hdr.sgml : 20250722 20250722163026 ACCESSION NUMBER: 0001356576-25-000046 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250722 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250722 DATE AS OF CHANGE: 20250722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 251140614 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 8-K 1 supn-20250722.htm 8-K supn-20250722 false 0001356576 0001356576 2025-07-22 2025-07-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 22, 2025   Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 9715 Key West Ave Rockville MD 20850 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: ( 301 ) 838-2500   Not Applicable (Former name or former address, if changed since last report.)   Securities registered pursuant to Section 12(b) of the Exchange Act Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Stock Market LLC Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. On July 22, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025. The Company will host a conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. E.T. to discuss its second quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit D

View on Read The Filing